Skip to main content

Our Journey
Our Technology
Pipeline

Leadership
Investors
Get in Touch

Press Releases

Presentations
Corporate Governance
Press Releases
Stock Information
SEC Filings

Investor Contact

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

Press Releases

Keyword Search

Year

Jun 02, 2023

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 09, 2023

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Apr 12, 2023

Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect

Mar 29, 2023

Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor

Mar 27, 2023

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 08, 2023

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 03, 2023

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

©2023 Kala Pharmaceuticals All rights reserved. June 2023

Terms of Use Privacy Statement Accessibility Policy